Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.

In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80

Deep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, Brazil. PLoS One (2014) 0.84

Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration. BMC Infect Dis (2011) 0.80

Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping. PLoS One (2015) 0.76

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS (2000) 4.55

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50

Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up. Eur Respir J (2011) 2.25

Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut (1991) 2.21

Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev (1995) 2.06

Large-scale production and physicochemical characterization of human immune interferon. Infect Immun (1979) 1.99

Thrombosis in the portal venous system after elective laparoscopic splenectomy. Surg Endosc (2004) 1.92

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS (1999) 1.89

Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans. Clin Microbiol Rev (2001) 1.83

Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis (2005) 1.58

General considerations of the interferon system. Tex Rep Biol Med (1977) 1.52

OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology (2010) 1.45

Immune interferon activates cells more slowly than does virus-induced interferon. Proc Soc Exp Biol Med (1978) 1.44

Hepatitis C virus treatment revolution: need for close monitoring. Clin Microbiol Infect (2014) 1.43

Plasma viraemia in seronegative HIV-1-infected individuals. AIDS (1991) 1.43

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med (2006) 1.43

Unexpectedly rapid action of human interferon in physiological conditions. Nature (1975) 1.41

Detection of respiratory viruses in the 2009 winter season in Rome: 2009 influenza A (H1N1) complications in children and concomitant type 1 diabetes onset. Int J Immunopathol Pharmacol (2011) 1.40

Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med (1999) 1.38

Unidirectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of intercellular adhesion molecules and HIV-1 viral matrix protein. AIDS (1995) 1.37

[Studying the course of HIV-1 infection in cell culture]. Orv Hetil (1993) 1.37

Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants. Arch Dis Child (2009) 1.37

Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol (2001) 1.31

A simple and reliable method to detect cell membrane proteins on infectious human immunodeficiency virus type 1 particles. J Infect Dis (1994) 1.27

High prevalence of TT virus viremia in italian patients, regardless of age, clinical diagnosis, and previous interferon treatment. J Infect Dis (1999) 1.25

Enzymatic induction of interferon production by galactose oxidase treatment of human lymphoid cells. Infect Immun (1979) 1.25

Subtype 2c of hepatitis C virus is highly prevalent in Italy and is heterogeneous in the NS5A region. J Clin Microbiol (1997) 1.25

Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol (1985) 1.24

Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr (2001) 1.24

Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. J Gen Virol (1993) 1.24

Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses (1990) 1.24

Determinants of health-related quality of life in HIV-infected patients. AIDS Care (2003) 1.22

Partial nucleotide sequencing of six subtype 2c hepatitis C viruses detected in Italy. J Clin Microbiol (1995) 1.20

CD8+ T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE. J Exp Med (1995) 1.16

Effect of DEAE-dextran on production of interferon induced by synthetic double-stranded RNA in L cell cultures. Proc Soc Exp Biol Med (1968) 1.16

TT virus (TTV) loads associated with different peripheral blood cell types and evidence for TTV replication in activated mononuclear cells. J Med Virol (2001) 1.16

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis (1991) 1.15

Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations. J Med Virol (2001) 1.14

Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses (1996) 1.14

Decreased interferon response by lymphocytes from children with chronic hepatitis. J Infect Dis (1975) 1.13

Immune and virus-induced interferons may activate cells by different derepressional mechanisms. Nature (1980) 1.12

Virus yield-reduction assay for interferon by titration of Sindbis virus hemagglutinin. Methods Enzymol (1981) 1.12

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol (1999) 1.12

Determination of the size of HIV using adenovirus type 2 as an internal length marker. J Virol Methods (1994) 1.12

Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS (2004) 1.12

A macrophage-derived factor different from interleukin 1 and able to induce interferon-gamma and lymphoproliferation in resting T lymphocytes. Cell Immunol (1988) 1.11

Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer. AIDS Res Hum Retroviruses (1992) 1.11

Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses (1998) 1.10

Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand (2002) 1.09

New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res (1996) 1.09

gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood (1998) 1.08

A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol (1994) 1.08

Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J Gen Virol (1997) 1.08

Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J Clin Microbiol (1993) 1.07

Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells. Am J Pathol (1994) 1.07

Effect of DEAE-dextran on interferon production and protective effect in mice treated with the double-stranded polynucleotide complex polyinosinic-polycytidylic acid. J Immunol (1969) 1.07

Human immune interferon: induction in lymphoid cells by a calcium ionophore. Infect Immun (1980) 1.07

Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood (1991) 1.07

Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines. AIDS (1998) 1.06

Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect (2010) 1.06

Dynamics of persistent TT virus infection, as determined in patients treated with alpha interferon for concomitant hepatitis C virus infection. J Virol (2001) 1.06

Acid-labile human interferon alpha production by peripheral blood mononuclear cells stimulated by HIV-infected cells. Arch Virol (1988) 1.05

C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol (1997) 1.05

Kaposi's sarcoma cells express the macrophage-associated antigen mannose receptor and develop in peripheral blood cultures of Kaposi's sarcoma patients. Am J Pathol (1997) 1.04

Generation of a soluble IFN-gamma inducer by oxidation of galactose residues on macrophages. Cell Immunol (1985) 1.03

Induction of an inhibitor of interferon action in a mouse lymphokine preparation. Infect Immun (1979) 1.03

Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol (1996) 1.03

Apoptosis-related mortality in vitro of mononuclear cells from patients with HIV infection correlates with disease severity and progression. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.02

Comparative evaluation of five rapid methods for identifying subtype 1b and 2c hepatitis C virus isolates. J Virol Methods (1997) 1.02

A protective effect of the Mediterranean diet for cutaneous melanoma. Int J Epidemiol (2008) 1.02

Hepatitis C virus infection in intravenous drug users: prevalence and risk factors. Scand J Infect Dis (1990) 1.02

Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol (1994) 1.02

MMTV-like sequences in human breast cancer: a fluorescent PCR/laser microdissection approach. J Pathol (2006) 1.02

gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology (2000) 1.02

Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis (2010) 1.02

Simple in vitro methods for titrating feline immunodeficiency virus (FIV) and FIV neutralizing antibodies. J Virol Methods (1992) 1.01

HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses (1995) 1.01

Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique. Health Educ Res (2005) 1.00

Recombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells; correlation with the induction of other cytokines. Clin Exp Immunol (1994) 1.00

Interferon induction by HIV glycoprotein 120: role of the V3 loop. Virology (1994) 0.99

Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol (1999) 0.99

A case of dengue type 3 virus infection imported from Africa to Italy, October 2009. Euro Surveill (2010) 0.98

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol (2002) 0.98